Review
doi: 10.1056/NEJMra013339.
Imatinib mesylate--a new oral targeted therapy
Affiliations
- PMID: 11870247
- DOI: 10.1056/NEJMra013339
Item in Clipboard
Review
Imatinib mesylate--a new oral targeted therapy
N Engl J Med.
.
No abstract available
Comment in
-
Imatinib and chronic-phase leukemias.N Engl J Med. 2002 Jul 4;347(1):67-8. doi: 10.1056/NEJM200207043470116. N Engl J Med. 2002. PMID: 12097546 No abstract available.
Similar articles
-
Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?Nat Clin Pract Oncol. 2005 Mar;2(3):126-7. doi: 10.1038/ncponc0110. Nat Clin Pract Oncol. 2005. PMID: 16264901 No abstract available.
-
Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.Clin Ther. 2004 Nov;26(11):1924-33. doi: 10.1016/j.clinthera.2004.11.007. Clin Ther. 2004. PMID: 15639704
-
The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.Health Technol Assess. 2002;6(33):1-162. doi: 10.3310/hta6330. Health Technol Assess. 2002. PMID: 12633529 Review. No abstract available.
-
Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).Ann Hematol. 2004;83 Suppl 1:S65-6. doi: 10.1007/s00277-004-0850-2. Ann Hematol. 2004. PMID: 15124676 Review. No abstract available.
-
Gleevec (STI-571) for chronic myeloid leukemia.Med Lett Drugs Ther. 2001 Jun 11;43(1106):49-50. Med Lett Drugs Ther. 2001. PMID: 11402258 No abstract available.
Cited by
-
Role of Sam68 in different types of cancer (Review).Int J Mol Med. 2025 Jan;55(1):3. doi: 10.3892/ijmm.2024.5444. Epub 2024 Oct 25. Int J Mol Med. 2025. PMID: 39450529 Free PMC article. Review.
-
The effectiveness of targeted therapy for recurrence or metastasis adenoid cystic carcinoma: a systematic review and meta-analysis.Ann Med. 2024 Dec;56(1):2399867. doi: 10.1080/07853890.2024.2399867. Epub 2024 Sep 11. Ann Med. 2024. PMID: 39258959 Free PMC article.
-
Discovery of therapeutic targets in cancer using chromatin accessibility and transcriptomic data.Cell Syst. 2024 Sep 18;15(9):824-837.e6. doi: 10.1016/j.cels.2024.08.004. Epub 2024 Sep 4. Cell Syst. 2024. PMID: 39236711
-
Advances in Personalized Oncology.Cancers (Basel). 2024 Aug 16;16(16):2862. doi: 10.3390/cancers16162862. Cancers (Basel). 2024. PMID: 39199633 Free PMC article. Review.
-
Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies.MedComm (2020). 2024 Aug 24;5(9):e694. doi: 10.1002/mco2.694. eCollection 2024 Sep. MedComm (2020). 2024. PMID: 39184861 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
